Quince Therapeutics (NASDAQ:QNCX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX) in a research note published on Friday morning,Benzinga reports. The firm currently has a $4.00 target price on the stock.

QNCX has been the topic of a number of other reports. Zacks Research upgraded shares of Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. JMP Securities reduced their price target on shares of Quince Therapeutics from $9.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Citigroup initiated coverage on shares of Quince Therapeutics in a research note on Tuesday, August 5th. They issued an “outperform” rating on the stock. Finally, Citizens Jmp initiated coverage on shares of Quince Therapeutics in a research note on Tuesday, August 5th. They issued a “strong-buy” rating and a $9.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $8.14.

Quince Therapeutics Trading Down 1.2%

Shares of Quince Therapeutics stock opened at $1.61 on Friday. The company has a market capitalization of $86.48 million, a price-to-earnings ratio of -1.48 and a beta of 0.99. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 1.45. Quince Therapeutics has a 12-month low of $0.69 and a 12-month high of $2.45. The firm’s 50-day moving average price is $1.65 and its two-hundred day moving average price is $1.40.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). On average, analysts forecast that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in Quince Therapeutics in the 2nd quarter valued at approximately $37,000. Two Sigma Investments LP bought a new position in Quince Therapeutics in the 4th quarter valued at approximately $57,000. Virtu Financial LLC raised its holdings in Quince Therapeutics by 48.4% in the 1st quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock valued at $58,000 after buying an additional 14,128 shares during the last quarter. Northern Trust Corp raised its holdings in Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after buying an additional 16,501 shares during the last quarter. Finally, Intellectus Partners LLC bought a new position in Quince Therapeutics in the 1st quarter valued at approximately $71,000. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.